Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
Argus Health
Healthtrust
Mallinckrodt
McKinsey
Accenture
Citi
Farmers Insurance

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,050,309

« Back to Dashboard

Which drugs does patent 9,050,309 protect, and when does it expire?

Patent 9,050,309 protects EPANOVA and is included in one NDA.

This patent has twenty-six patent family members in twenty-two countries.
Summary for Patent: 9,050,309
Title:DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Inventor(s): Maines; Timothy J. (Potomac, MD), Machielse; Bernardus N M (North Potomac, MD), Mehta; Bharat M. (Mendham, NJ), Wisler; Gerald L. (Windermere, FL), Davidson; Michael H. (Highland Park, IL), Wood; Peter Ralph (Cotherstone, GB)
Assignee: Omthera Pharmaceuticals, Inc. (Princeton, NJ) Chrysalis Pharma AG (Sacheln, CH)
Application Number:13/797,557
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,050,309

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,050,309

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,050,308 DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Merck
Fish and Richardson
Boehringer Ingelheim
AstraZeneca
Accenture
UBS
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.